Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis.
D000328:Adult; D000077944:Alefacept; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000473:pathology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects* / Q000473:pathology; D019040:E-Selectin / Q000378:metabolism; D004817:Epidermis / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007156:Immunologic Memory / Q000187:drug effects; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome; D019010:Vascular Cell Adhesion Molecule-1 / Q000378:metabolism
D019040:E-Selectin; D011993:Recombinant Fusion Proteins; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1; D000077944:Alefacept